Vir Biotechnology (NASDAQ:VIR) CEO Sells $141,840.55 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 19,039 shares of Vir Biotechnology stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $141,840.55. Following the completion of the sale, the chief executive officer owned 1,035,466 shares of the company’s stock, valued at $7,714,221.70. This represents a 1.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Vir Biotechnology Stock Performance

Shares of VIR traded up $2.06 during mid-day trading on Tuesday, hitting $9.49. 38,240,174 shares of the company traded hands, compared to its average volume of 1,972,225. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69. The stock has a 50-day moving average price of $6.80 and a two-hundred day moving average price of $5.99. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.29.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 47.14%. The firm’s revenue was up 417.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.76) EPS. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on VIR shares. Evercore reissued an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. Needham & Company LLC upped their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Barclays restated an “overweight” rating and set a $30.00 target price on shares of Vir Biotechnology in a research report on Tuesday. Finally, Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.88.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently added to or reduced their stakes in VIR. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Vir Biotechnology in the 3rd quarter worth $38,000. Raymond James Financial Inc. purchased a new stake in Vir Biotechnology in the 2nd quarter worth $35,000. UMB Bank n.a. increased its stake in Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after buying an additional 6,597 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Vir Biotechnology by 153.8% during the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after acquiring an additional 4,899 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.